{"id":118,"date":"2007-11-15T08:00:26","date_gmt":"2007-11-15T08:00:26","guid":{"rendered":"https:\/\/palladiumcapital.com\/wp-padium\/?p=118"},"modified":"2013-08-04T03:00:34","modified_gmt":"2013-08-04T03:00:34","slug":"palladium-capital-is-pleased-to-announce-a-1165525-equity-raise-for-genelink-inc","status":"publish","type":"post","link":"https:\/\/www.palladiumcapital.com\/palladium-capital-is-pleased-to-announce-a-1165525-equity-raise-for-genelink-inc\/","title":{"rendered":"Palladium Capital is Pleased to Announce a $1,165,525 Equity Raise for GeneLink, Inc."},"content":{"rendered":"

\"tomb_genelink\"<\/a>On November 13, 2007, GeneLink, Inc. (“GeneLink” or the “Company”) completed a private placement (the “Private Placement”), for which Palladium Capital, LLC (“Palladium”), acted as the co-placement agent. The Private Placement consisted of the sale of 15,540,328 units (the “Units”), each Unit consisting of one (1) share of Common Stock of the Company and a warrant to acquire 1\/4 of one (1) share of Common Stock of the Company at an exercise price of $0.10 per share. The offering price per Unit is $0.075. (the “Unit Issue Price”) or $1,165,524.66 in the aggregate. A total of 15,540,328 shares of Common Stock of the Company and warrants to acquire a total of 3,885,082 shares of Common Stock of the Company were issued to the investors who acquired Units.<\/p>\n

The Units were offered and sold to accredited investors (the “Investors”) as defined in Regulation D as promulgated under the Securities Act of 1933, as amended. Holders of the Units will not have any demand registration rights with respect to any of the shares of Common Stocks or Warrants issued as part of the Units.<\/p>\n

The Company intends to use the proceeds of the offering to fund, among other things: adding infrastructure to support the Company’s existing and anticipated licensing agreements; the development and pursuit of its redirected business plans, including the pursuit of new revenue producing distribution channels; the support and enhancement of the Company’s intellectual property portfolio; working capital requirements; corporate overhead, including professional fees and expenses; and the payment of outstanding payables and trade debt.<\/p>\n","protected":false},"excerpt":{"rendered":"

On November 13, 2007, GeneLink, Inc. (“GeneLink” or the “Company”) completed a private placement (the “Private Placement”), for which Palladium Capital, LLC (“Palladium”), acted as the co-placement agent. The Private Placement consisted of the sale of 15,540,328 units (the “Units”), each Unit consisting of one (1) share of Common Stock of the Company and a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/118"}],"collection":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/comments?post=118"}],"version-history":[{"count":0,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/118\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/media?parent=118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/categories?post=118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/tags?post=118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}